Market capitalization | $2.02b |
Enterprise Value | $1.82b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 36.05 |
EV/Sales (TTM) EV/Sales | 10.03 |
P/S ratio (TTM) P/S ratio | 11.15 |
P/B ratio (TTM) P/B ratio | 2.54 |
Revenue growth (TTM) Revenue growth | 53.40% |
Revenue (TTM) Revenue | $181.49m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
7 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:
7 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:
Mar '25 |
+/-
%
|
||
Revenue | 181 181 |
53%
53%
|
|
Gross Profit | 135 135 |
79%
79%
|
|
EBITDA | 21 21 |
42%
42%
|
EBIT (Operating Income) EBIT | -17 -17 |
1,091%
1,091%
|
Net Profit | -133 -133 |
238%
238%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Todd Davis |
Employees | 68 |
Founded | 1987 |
Website | www.ligand.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.